medigraphic.com

2003, Number s1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2003; 41 (s1)

Clinical Guideline for Diagnosis and Treatment of High Blood Pressure

Oviedo MMA, Espinosa LF, Olivares SR, Reyes MH, Trejo y PJA

Language: Spanish
References: 50
Page: 15-26
PDF size: 225.32 Kb.


ABSTRACT

The timely identification and adequate treatment of high blood pressure are critical for reducing the risk of cardiovascular disease as well as morbidity and mortality associated with the illness. A positive relationship has been identified between elevated systolic and diastolic arterial pressure and cardiovascular risk, and this relationship is strong, consistent, predictive, and significantly etiologic for individuals with or without coronary illness. This set of clinical practice guidelines presents recommendations for detection, diagnosis, and comprehensive management of arterial hypertension. Best practices were selected from publications appearing in Cochrane Library, Medline, and other published guidelines from 1990 to 2002. Criteria from national reviews in the U.S. and Canada as well as modification of the Mexican Official Norm for Prevention, Treatment, and Control of High Blood Pressure also were consulted. The guidelines highlight the importance of detection, comprehensive classification including evaluation of cardiovascular risk factors, and presence of damage to the target organ, as well as treatment that combines changes in lifestyle and use of medications.


REFERENCES

  1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-2446.

  2. Subsecretaría de Prevención y Control de Enfermedades, Coordinación de Vigilancia Epidemiológica. Proyecto de norma oficial mexicana para la prevención, tratamiento y control de la hipertensión arterial. México: SSa; 1999.

  3. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, et al. Human blood pressure determination by sphygmonametry. Circulation 1993;88: 2460-2470.

  4. Tsuji I, Imai Y, Nagai K, et al. Proposal of reference values for home blood pressure measurement: prognostic criteria based on a prospective observation of the general population in Ohasama, Japan. Am J Hypertens 1997;10:409-418.

  5. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med 2002; 136:493-503.

  6. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the Trials of Hypertension Prevention, phase II. Arch Intern Med 1997;157:657-667.

  7. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith-West D, et al. Trials for the Hypertension Prevention Research Group. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001;134:72-74.

  8. He J, Whelton PK, Appel LJ, Charleston J, Klag MJ, Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000;35:544-549.

  9. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK, Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38:1112-1117.

  10. Cutler JA, Follman D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997;65 (Suppl 2):643S-651S.

  11. Graudal NA, Galloe AM, Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglycerides: a meta-analysis. JAMA 1998;279:1383- 1391.

  12. Midgley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275:1590-1597.

  13. Whelton PK, He J, Cutler JA, Brancati FL, Appel LJ, Follmann D, et al. Effects of oral potassium on blood pressure: meta-analysis of randomized controlled trials. JAMA 1997;277:1624-1632.

  14. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al.; For the DASH Colla-borative Research Group. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997;336:1117-1124.

  15. Whelton PK, He J, Appel LJ, et al. Primary prevention of hypertension: clinical and public health advisory from the national high blood pressure education program. JAMA 2002;288(15):1882-1888.

  16. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995;155:701-709.

  17. Cheng A, Braunstein J, Dennison Ch, Nass C, Blumenthal RS. Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy. Clin Cardiol 2002;25:205-212.

  18. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002;25 (Suppl 1):S1-S147.

  19. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-661.

  20. Campbell N, Drouin D, Feldman R. The 2001 Canadian hypertension recommendations: takehome messages. Can Med Assoc J 2002;167(6):661- 668.

  21. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al.; For the Treatment of Mild Hypertension Study Research Group. Treatment of mild hypertension study: final results. JAMA 1993;270:713-724.

  22. Singer DRJ, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, Mac Gregor GA. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of thiazide. Hypertension 1995;25:1042-1044.

  23. Dickey RA, Janick JJ. Lifestyle modifications in the prevention and treatment of hypertension. Endocrine Practice 2001;7(5):392-399.

  24. Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: the trials of Hypertension Prevention, phase II. Arch Intern Med 1997; 157:657-667.

  25. Leiter LA, Abbott D, Campbell NR, Mendelson R, Ogilvie RI, Chockalingam A. Lifestyle modifications to prevent and control hypertension. 2. Recommendations on obesity and weight loss. Canadian Hypertension Society, Canadian Coalition for high blood pressure prevention and control. Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999;160:S7-S12.

  26. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.

  27. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WC. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22.

  28. Stamler J, Caggiula AW, Grandits GA. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the multiple risk factor intervention trial. Am J Clin Nutr 1997; 65 (Suppl):338S-365S.

  29. Puddey IB, Parker M, Beilen LJ, Vandongen R, Masarei JRL. Effects of alcohol and caloric restrictions on blood pressure and serum lipids in overweight men. Hypertension 1992;20:533-541.

  30. Gill JS, Shipley MJ, Tsementzis SA, et al. Alcohol consumption a risk factor for hemorrhagic and nonhemorrhagic stroke. Am J Med 1991;90:489-497.

  31. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women: the role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. New Engl J Med 1990;322:95-99.

  32. Sesso H, Stampfer MJ, Rosner B, Hennekens Ch, Manson JA, Gaziano M. Seven-year changes in alcohol consumption and subsequent risk of cardiovascular disease in men. Arch Intern Med 2000;160 (17):2605-2612.

  33. Fletcher G. Physical activity as a risk factor for cardiovascular disease. Am J Med 1999;107:10-11.

  34. Leon AS, Connett J. Physical activity and 10.5 year mortality in the multiple risk factor intervention trial. Int J Epidemiol 1991;20:690-697.

  35. Elliott P, Stamler J, Nichols R, Dyer AR, Stamler R, Kesteloot H, et al.: For the Intersalt Cooperative Research Group. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. BMJ 1996;312:1249- 1253.

  36. Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overweight. Am J Clin Nutr 1997;65 (Suppl):643S-651S.

  37. Midglegley JP, Matthew AG, Greenwood CM, Logan AG. Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. JAMA 1996;275(20):1590-1597.

  38. Thomas D. Tobacco smoking and cardiovascular diseases. Revue du Practicien 1993;43(10):1218-1222.

  39. Westman EC. Does smokeless tobacco cause hypertension? Southern Medical Association Journal 1995;88(7):716-720.

  40. US Department of Health and Human Services. The health benefits of smoking cessation. Atlanta, Georgia: US Department of Health and Human Services, CDC, National Center for Chronic Diseases Prevention and Health Promotion, Office on Smoking and Health; 1990.

  41. van-Montfrans GA, Karemaker JM, Wieling W, Dunning AJ. Relaxation therapy and continuous ambulatory blood pressure in mild hypertension: a controlled study. BMJ 1990;300:1368-1372.

  42. Alexander CN, Schneider RH, Staggers F, Sheppard W, Clayborne M, Rainforth M, et al. Trial of stress reduction for hypertension in older African Americans. Hypertension 1996;28:228-237.

  43. Spence JD, Barnett PA, Linden W, Ramsden V, Taenzer P. Lifestyle modifications to prevent and control hypertension. Recommendations on stress management. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundation of Canada. CMAJ 1999;160 (9 Suppl): S46-S50.

  44. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and metaanalysis. JAMA 1997;277:739-745.

  45. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27:1214-1218.

  46. Mulrow C, Lau J, Cornell J, Brand M. Pharmacotherapy for hypertension in the elderly (Cochrane Review). En: The Cochrane Library, Issue 4, 2002. Oxford: Update Software.

  47. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a metaanalysis. Lancet 2001;358:1305-1315.

  48. Quan A, Kerlikowske K, Gueyffier F, Boissel JP, INDANA Investigators. Pharmacotherapy for hypertension in women of different races (Cochrane Review). En: The Cochrane Library, Issue 4,2002. Oxford: Update Software.

  49. Institute for Clinical Systems Improvement. Health Care Guideline: Hypertension Diagnosis and Treatment. ICSI 2002. http://www.icsi.org/knowledge/ detail.asp

  50. Neutel JM. The use of combination drug therapy in the treatment of hypertension. Prog Cardiovasc Nurs 2002;17(2):81-88.




2020     |     www.medigraphic.com